Haemonetics announces Q2 FY2025 results; specific figures unavailable from provided filing text

HAEMONETICS CORP

2025-Q2 EPS reported $1.40 vs consensus $1.03 ▲ beat (+36.4%)

Company issued press release for quarter ended Sept 28, 2024 and first half of fiscal 2025.
No revenue, EPS, or segment data are included in the 8-K filing text provided.
Investors should consult the full press release for detailed financial results.
CEO Christopher A. Simon signed the Form 8-K on November 7, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.